**Supplementary table 2:** Comparison of LDH between diagnosis, sex, age, smoking status and disease duration within a medication group

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Parameter** | **Lab marker** | **Medication** | **GMR (95% CI)** | **p-value** |
| Diagnosis (CD vs. UC) | LDH | InfliximabVedolizumab | 1.04 (0.97; 1.13)1.06 (0.91; 1.23) | 0.280.48 |
| Sex (male vs. female) | LDH | InfliximabVedolizumab | 1.00 (0.93; 1.08)1.05 (0.90; 1.22) | 0.940.57 |
| Age | LDH | InfliximabVedolizumab | 1.01 (1.00; 1.01)1.00 (1.00; 1.01) | <0.001\*0.44  |
| Smoker (yes vs. no) | LDH | InfliximabVedolizumab | 0.99 (0.92; 1.07)1.01 (0.87; 1.19) | 0.840.86  |
| Smoker (ex vs. no) | LDH | InfliximabVedolizumab | 0.96 (0.87; 1.05)1.03 (0.82; 1.30) | 0.370.79  |
| Disease duration | LDH | InfliximabVedolizumab | 0.99 (0.99; 1.00)1.00 (1.00; 1.01) | 0.005\*0.31 |